155 related articles for article (PubMed ID: 32988235)
1. Liquid biopsy for ALK-positive early non-small-cell lung cancer predicts disease relapse.
Li J; Dong W; Liu LN; Huang YJ; Xiao MF
Future Oncol; 2021 Jan; 17(1):81-90. PubMed ID: 32988235
[No Abstract] [Full Text] [Related]
2. Concordance of anaplastic lymphoma kinase (ALK) gene rearrangements between circulating tumor cells and tumor in non-small cell lung cancer.
Tan CL; Lim TH; Lim TKh; Tan DS; Chua YW; Ang MK; Pang B; Lim CT; Takano A; Lim AS; Leong MC; Lim WT
Oncotarget; 2016 Apr; 7(17):23251-62. PubMed ID: 26993609
[TBL] [Abstract][Full Text] [Related]
3. Circulating Cell-Free DNA and Circulating Tumor Cells as Prognostic and Predictive Biomarkers in Advanced Non-Small Cell Lung Cancer Patients Treated with First-Line Chemotherapy.
Coco S; Alama A; Vanni I; Fontana V; Genova C; Dal Bello MG; Truini A; Rijavec E; Biello F; Sini C; Burrafato G; Maggioni C; Barletta G; Grossi F
Int J Mol Sci; 2017 May; 18(5):. PubMed ID: 28492516
[TBL] [Abstract][Full Text] [Related]
4. A Prospective Evaluation of Circulating Tumor Cells and Cell-Free DNA in EGFR-Mutant Non-Small Cell Lung Cancer Patients Treated with Erlotinib on a Phase II Trial.
Yanagita M; Redig AJ; Paweletz CP; Dahlberg SE; O'Connell A; Feeney N; Taibi M; Boucher D; Oxnard GR; Johnson BE; Costa DB; Jackman DM; Jänne PA
Clin Cancer Res; 2016 Dec; 22(24):6010-6020. PubMed ID: 27281561
[TBL] [Abstract][Full Text] [Related]
5. Association of circulating tumour cells with early relapse and 18F-fluorodeoxyglucose positron emission tomography uptake in resected non-small-cell lung cancers.
Bayarri-Lara CI; de Miguel Pérez D; Cueto Ladrón de Guevara A; Rodriguez Fernández A; Puche JL; Sánchez-Palencia Ramos A; Ruiz Zafra J; Giraldo Ospina CF; Delgado-Rodríguez M; Expósito Ruiz M; Moyano Rodriguez MJ; Lorente JA; Serrano MJ
Eur J Cardiothorac Surg; 2017 Jul; 52(1):55-62. PubMed ID: 28369376
[TBL] [Abstract][Full Text] [Related]
6. Acquired Resistance Mutations to ALK Inhibitors Identified by Single Circulating Tumor Cell Sequencing in
Pailler E; Faugeroux V; Oulhen M; Mezquita L; Laporte M; Honoré A; Lecluse Y; Queffelec P; NgoCamus M; Nicotra C; Remon J; Lacroix L; Planchard D; Friboulet L; Besse B; Farace F
Clin Cancer Res; 2019 Nov; 25(22):6671-6682. PubMed ID: 31439588
[TBL] [Abstract][Full Text] [Related]
7. Prognostic role of circulating tumor cells in patients with EGFR-mutated or ALK-rearranged non-small cell lung cancer.
Tong B; Xu Y; Zhao J; Chen M; Zhong W; Xing J; Wang M
Thorac Cancer; 2018 May; 9(5):640-645. PubMed ID: 29582563
[TBL] [Abstract][Full Text] [Related]
8. Circulating cell-free nucleic acids and platelets as a liquid biopsy in the provision of personalized therapy for lung cancer patients.
Sorber L; Zwaenepoel K; Deschoolmeester V; Van Schil PE; Van Meerbeeck J; Lardon F; Rolfo C; Pauwels P
Lung Cancer; 2017 May; 107():100-107. PubMed ID: 27180141
[TBL] [Abstract][Full Text] [Related]
9. Use of capture-based next-generation sequencing to detect ALK fusion in plasma cell-free DNA of patients with non-small-cell lung cancer.
Cui S; Zhang W; Xiong L; Pan F; Niu Y; Chu T; Wang H; Zhao Y; Jiang L
Oncotarget; 2017 Jan; 8(2):2771-2780. PubMed ID: 27926526
[TBL] [Abstract][Full Text] [Related]
10. High level of chromosomal instability in circulating tumor cells of ROS1-rearranged non-small-cell lung cancer.
Pailler E; Auger N; Lindsay CR; Vielh P; Islas-Morris-Hernandez A; Borget I; Ngo-Camus M; Planchard D; Soria JC; Besse B; Farace F
Ann Oncol; 2015 Jul; 26(7):1408-15. PubMed ID: 25846554
[TBL] [Abstract][Full Text] [Related]
11. Circulating Tumor Cells Identify Early Recurrence in Patients with Non-Small Cell Lung Cancer Undergoing Radical Resection.
Bayarri-Lara C; Ortega FG; Cueto Ladrón de Guevara A; Puche JL; Ruiz Zafra J; de Miguel-Pérez D; Ramos AS; Giraldo-Ospina CF; Navajas Gómez JA; Delgado-Rodriguez M; Lorente JA; Serrano MJ
PLoS One; 2016; 11(2):e0148659. PubMed ID: 26913536
[TBL] [Abstract][Full Text] [Related]
12. Highly sensitive detection of ALK resistance mutations in plasma using droplet digital PCR.
Yoshida R; Sasaki T; Umekage Y; Tanno S; Ono Y; Ogata M; Chiba S; Mizukami Y; Ohsaki Y
BMC Cancer; 2018 Nov; 18(1):1136. PubMed ID: 30453899
[TBL] [Abstract][Full Text] [Related]
13. The Effects of Different Surgical Approaches on the Perioperative Level of Circulating Tumor Cells in Patients with Non-Small Cell Lung Cancer.
Huang HB; Ge MJ
Thorac Cardiovasc Surg; 2016 Sep; 64(6):515-9. PubMed ID: 26030121
[TBL] [Abstract][Full Text] [Related]
14. Can cell-free DNA (cfDNA) in pleural lavage serve as a predictive and prognostic biomarker among surgically treated Stage I-III a nonsmall cell lung cancer (NSCLC)? A pilot study.
Saikia J; Malik PS; Kumar S; Jain D; Madan K; Bharati SJ; Deo S; Kumar S
J Surg Oncol; 2024 Jun; 129(7):1224-1234. PubMed ID: 38436618
[TBL] [Abstract][Full Text] [Related]
15. Cell-Free Circulating Tumor DNA Improves Standard Genotyping of Non-Small-Cell Lung Cancer and Increases Detection of Targetable Alterations in a Selected Hispanic Cohort.
Zatarain-Barrón ZL; Cardona AF; Díaz-García D; Trejo Rosales R; Rojas L; Cruz-Rico G; Nagy R; Cabrera L; Vargas C; Saam J; Barrón F; Arrieta O
Oncology; 2021; 99(8):539-546. PubMed ID: 33902046
[TBL] [Abstract][Full Text] [Related]
16. DNA methylation analysis of tumor suppressor genes in liquid biopsy components of early stage NSCLC: a promising tool for early detection.
Markou Α; Londra D; Tserpeli V; Kollias Ι; Tsaroucha E; Vamvakaris I; Potaris K; Pateras I; Kotsakis Α; Georgoulias V; Lianidou Ε
Clin Epigenetics; 2022 May; 14(1):61. PubMed ID: 35538556
[TBL] [Abstract][Full Text] [Related]
17. The Use of Three-Dimensional DNA Fluorescent In Situ Hybridization (3D DNA FISH) for the Detection of Anaplastic Lymphoma Kinase (ALK) in Non-Small Cell Lung Cancer (NSCLC) Circulating Tumor Cells.
Kulasinghe A; Lim Y; Kapeleris J; Warkiani M; O'Byrne K; Punyadeera C
Cells; 2020 Jun; 9(6):. PubMed ID: 32549278
[TBL] [Abstract][Full Text] [Related]
18. Clinical outcomes of patients with resected, early-stage ALK-positive lung cancer.
Chaft JE; Dagogo-Jack I; Santini FC; Eng J; Yeap BY; Izar B; Chin E; Jones DR; Kris MG; Shaw AT; Gainor JF
Lung Cancer; 2018 Aug; 122():67-71. PubMed ID: 30032847
[TBL] [Abstract][Full Text] [Related]
19. Clinical potential of circulating free DNA and circulating tumour cells in patients with metastatic non-small-cell lung cancer treated with pembrolizumab.
Mondelo-Macía P; García-González J; León-Mateos L; Anido U; Aguín S; Abdulkader I; Sánchez-Ares M; Abalo A; Rodríguez-Casanova A; Díaz-Lagares Á; Lago-Lestón RM; Muinelo-Romay L; López-López R; Díaz-Peña R
Mol Oncol; 2021 Nov; 15(11):2923-2940. PubMed ID: 34465006
[TBL] [Abstract][Full Text] [Related]
20. Clinical significance of circulating tumor cells and free DNA in non-small cell lung cancer.
Isobe K; Hata Y; Kobayashi K; Hirota N; Sato K; Sano G; Sugino K; Sakamoto S; Takai Y; Shibuya K; Takagi K; Homma S
Anticancer Res; 2012 Aug; 32(8):3339-44. PubMed ID: 22843912
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
